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Abstract. Background: The 5-year survival rate of patients
with oral cancer has remained approximately 50% during
the past 30 years, possibly due to the poor tumor selectivity
of conventional anticancer drugs. This prompted us to search
for new candidates for anticancer drugs that have higher
cytotoxicity and tumor selectivity. Materials and Methods:
Dried leaves of Andrographis paniculata were supplied from
a market in Shanghai. The methanolic fraction of A.
paniculata was further fractionated to identify cytotoxic
principles by spectroscopic analysis and comparison with
literature values. Viable cell number was determined by the
3-[4,5-dimethylthiazol-2-yl]-2,5-diphenyltetrazolium bromide
method, and tumor specificity was calculated by relative
cytotoxicity against oral squamous cell carcinoma cell lines
compared to that against normal oral cells. Apoptosis
induction was detected by cleaved poly (ADP-ribose)
polymerase and caspase-3 on western blot analysis. Results:
Major cytotoxicity in the methanol extract of a leaf of A.
paniculata was recovered by partitioning with EtOAc,
followed by silica gel chromatography. Further purification
with reversed-phase high-performance liquid
chromatography led to isolation of four known cytotoxic
compounds, 14-deoxyandrographolide, andrographolide,
neoandrographolide and deoxyandrographiside. Among
them, andrographolide had the greatest cytotoxicity and
tumor specificity, also inducing caspase-3 activation of HSC-
2 oral squamous cell carcinoma cells. Conclusion: The
present study identified andrographolide as a major
antitumor principle in the methanolic extract of leaves of A.
paniculata.
Head and neck cancer is the sixth most common malignancy,
compromising approximately 6% of all cancer cases (1), and
mostly comprised of heterogeneous populations of oral
squamous cell carcinomas (1, 2). At the early stage of oral
cancer progression, surgery and radiation are the most
popular choice of antitumor treatment (2), but they may
cause disfiguring and psychological trauma in patients.
Therefore, the development of new treatment strategies and
the early diagnosis of oral cancer are of great importance (3).
We have initiated a series of studies to search for new natural
substances for the treatment of oral cancer, using an in vitro
evaluation system with human oral squamous cell carcinoma
cell lines (HSC-2, HSC-3 and HSC-4) and human normal
oral cells (gingival fibroblast, HGF; periodontal ligament
fibroblast, HPLF; pulp cell, HPC). Since the methanolic
extract of Andrographis paniculata was found to have
relatively higher cytotoxic activity, we isolated and identified
the cytotoxic principles present in this extract, and also
investigated the possibility of apoptosis induction of HSC-2
cells by compound isolated from this extract. 
Materials and Methods
Materials. The following chemicals and reagents were obtained from
the indicated companies: Dulbecco’s modified Eagle's medium
(DMEM; Gibco BRL, Grand Island, NY, USA); fetal bovine serum
(FBS; JRH Bioscience, Lenexa, KS, USA); 5-fluorouracil (5-FU;
Kyowa, Tokyo, Japan); doxorubicin hydrochloride (Wako Pure
Chem. Ind., Osaka, Japan); dimethyl sulfoxide (DMSO; Wako Pure
Chem. Ind.); DMSO-d6, CD3OD (Cambridge Isotope Laboratories,
Inc., MA, USA) and pyridine-d5 (ACROS organics, Geel, Belgium);
silica gel (Fuji Silysia Chemical LTD., Aichi, Japan) and silica gel
plate (Merck KGaA, Damstadt, Germany). Protease and phosphatase
inhibitors were purchased from Roche Diagnostics (Tokyo, Japan).
Antibodies against cleaved caspase-3 (Cell Signaling Technology
Inc., Beverly, Maryland), poly (ADP-ribose) polymerase (PARP)
(Cell Signaling Technology Inc') and glyceraldehyde 3-phosphate
dehydrogenase (GAPDH; Trevigen, Gaithersburg, MD, USA) were
used as primary antibodies. As secondary antibodies, we used α-
rabbit IgG (DAKO Japan) antibodies which were conjugated with
horseradish peroxidase.
5931
Correspondence to: Professor Yoshiaki Shirataki, Faculty of
Pharmaceutical Sciences, Josai University, 1-1 Keyakidai, Sakado,
Saitama 350-0295, Japan. Tel: +81 492717053, Fax: +81
492717984, e-mail: shiratak@josai.ac.jp 
Key Words: Andrographis paniculata, cytotoxicity, human oral
squamous cell carcinoma.
ANTICANCER RESEARCH 36: 5931-5936 (2016)
doi:10.21873/anticanres.11180
Cytotoxic Components Against Human Oral Squamous 
Cell Carcinoma Isolated from Andrographis paniculata
RYUICHIRO SUZUKI1, YASUAKI MATSUSHIMA1, NORIYUKI OKUDAIRA2, 
HIROSHI SAKAGAMI2 and YOSHIAKI SHIRATAKI1
1Faculty of Pharmaceutical Sciences, Josai University, Sakado, Japan;
2Division of Pharmacology, Meikai University School of Dentistry, Sakado, Japan 
0250-7005/2016 $2.00+.40
General experimental procedures. Nuclear magnetic resonance (NMR)
spectra were measured on a 400 MHz Agilent-400MR-vnmrs 400
spectrometer (Agilent Technologies, Santa Clara, CA, USA) at room
temperature using standard pulse sequences. Electron ionization-mass
spectra (EI-MS) were measured with a JEOL JMN 700 spectrometer
(JEOL Ltd., Tokyo, Japan). Electrospray ionization (ESI)-MS was also
measured with an API4000-QTRP (AB SCIEX, CA, USA). Open
column chromatography was performed on silica gel. High-
performance liquid chromatography (HPLC) was performed with
Senshu Pak ODS column (4.6 mm i.d. × 150 mm for analysis, 10 mm
i.d. ×250 mm for preparation; Senshu Scientific Co., Ltd., Tokyo,
Japan). AQUASIL SP100 (10 mm i.d. × 250 mm; Senshu Scientific
Co., Ltd.) was also used as preparative column for HPLC purification. 
Plant materials. The dried leaves of A. paniculata were supplied
from a market in Shanghai. The specimen was proven and identified
by Dr. Y. Shirataki and voucher specimens (#20140521) were also
deposited in the Department of Pharmacognosy and Natural
Medicines of Josai University. 
Preparation of methanolic extract. Methanolic extract of leaves of
A. paniculata (3 kg) was prepared by extraction with MeOH under
reflux for 3 h. This extract was completely dried in vacuo to give
the corresponding dried extract (146 g).
Isolation of components from methanolic extract. The methanolic
extract was suspended in water, then extracted with EtOAc and n-
BuOH, successively. Each soluble portion was evaporated in vacuo
to give EtOAc (57.2 g) and n-BuOH (43.1 g) fractions, respectively.
The EtOAc fraction was chromatographed on a silica gel column by
step-wise elution with a CHCl3-MeOH mixture (CHCl3:
MeOH=100:1 → 1:1 → 1:3) to give three fractions (Fr 1-3). Fr 2 (31.2
g) was further purified with silica gel open-column chromatography
eluting with CHCl3-MeOH mixture (CHCl3: MeOH=100:1 → 50:1 →
30:1 → 15:1 → 7:1 → 3:1 → 0:1) to provide seven further fractions
(Fr. 2-1-2-7). Fr. 2-1 (0.92 g) and Fr. 2-2 (1.4 g) combined with Fr.
2-3 (1.0 g) were purified by reversed-phase HPLC, eluting with a
MeCN-H2O mixture, to afford compound 1 (87.8 mg) and 2 (123.8
mg) respectively. Fr. 2-4 (1.5 g) was subjected to reversed-phase
HPLC using aqueous MeCN as solvent system to give compound 3
(21.4 mg). Fr. 2-5 (2.8 g) was rechromatographed on silica gel open
column eluting with CHCl3-MeOH mixture (CHCl3: MeOH=6:1→
3:1 → 0:1) to provide three fractions (Fr. 2-5-1 – 2-5-3). Fr. 2-5-1 was
purified with HPLC (AQUASIL SP100, 10 mm i.d. × 250 mm,
CHCl3-MeOH mixture) to give compound 4 (54.3 mg). 
Cell culture. Human oral squamous cell carcinoma cell lines (HSC-
2, HSC-3, HSC-4) were purchased from Riken Cell Bank (Tsukuba,
Ibaraki, Japan). Normal human oral cells, HGF, HPLF and HPC were
prepared from periodontal tissues, according to the guideline of the
Intramural Ethic Committee (No. A0808), after obtaining informed
consent from the 12-year-old patient at the Meikai University
Hospital (4). Since normal oral cells have a limited lifespan of 43-47
population doubling levels (PDL) (4), they were used at 8-15 PDL in
this study. All the cells were cultured in DMEM supplemented with
10% heat-inactivated FBS, 100 U/ml penicillin G and 100 μg/ml
streptomycin sulfate. The normal cells were detached by 0.25%
trypsin-0.025% EDTA-2Na in phosphate-buffered saline without
Mg2+ and Ca2+ [PBS(–)] and subcultured at a 1:4 split ratio once a
week, with a medium change between the subcultures. 
Assay for cytotoxic activity. The cells were seeded (2.5×103
cells/well, 0.1 ml/well) in 96-microwell plates (Becton Dickinson
and Company, Franklin Lakes, NJ, USA) and incubated for 48 h to
allow cell attachment. Near-confluent cells were treated for 48 h
with different concentrations of the test compounds in fresh
medium. The relative viable cell number of adherent cells was then
determined by the 3-[4,5-dimethylthiazol-2-yl]-2,5-diphenyltetra-
zolium bromide (MTT) method (5). In brief, control and treated
cells were incubated for 4 h with 0.2 mg/ml of MTT in the culture
medium. After removing the medium, the reaction product,
formazan, was extracted with DMSO and the absorbance
(corresponding to the relative viable cell number) was measured at
540 nm by a microplate reader (Multiskan Bichromatic Labsystems,
Helsinki, Finland). The 50% cytotoxic concentration (CC50) was
determined from the dose–response curve. The tumor-specificity
(TS) was calculated by the following equation: TS=mean CC50
(normal cells)/mean CC50 (all tumor cell lines).
Western blott analysis. The cells were washed with PBS and
resuspended in 50 mM Tris-HCl (pH 7.6), 150 mM NaCl, 1 mM
EDTA, 0.1% SDS, 0.5% deoxycholic acid, 1% NP-40, and protease
inhibitors (RIPA buffer). After ultrasonication using Bioruptor
(UCD-250, Cosmo Bio Tokyo, Japan) for 12.5 min (10 s on, 20 s
off) at the middle level of output (250 W) at 4˚C. The soluble
cellular extracts were recovered after centrifugation for 10 min at
16,000 × g. The protein concentration of each sample was
determined using BCA Protein Assay Reagent Kit (Thermo Fisher
Scientific Waltham, MA, USA), and cell extracts were subjected to
western blot analysis. The blots were probed with primary antibody
against PARP or caspase-3 followed by a horseradish peroxidase-
conjugated secondary antibody. The immune complexes were
visualized using Pierce Western Blotting Substrate Plus (Thermo
Fisher Scientific). Western blot results were documented and
quantified using ImageQuant LAS 500 (GE Healthcare Japan,
Tokyo, Japan).
Statistical treatment. Experimental values are expressed as the
mean±standard deviation (SD). Statistical analysis was performed
by using Student’s t-test. A p-value of less than 0.05 was considered
to be significant.
Results
Isolation of active components. During the search for
candidate natural products for the treatment of oral cancer,
methanolic extract of A. paniculata was found to show
slightly higher cytotoxic activity against oral squamous cell
carcinoma (HSC-2, HSC-3 and HSC-4) than human oral
normal cells (HGF, HPLF, HPC), with an approximate TS
of 3 (Table I). When the MeOH extract was partitioned
with successive organic solvents, the EtOAc-soluble
fraction had the strongest cytotoxicity. Therefore, the
EtOAc-soluble fraction was further purified to yield three
fractions. Among of them, Fr. 2 exhibited the strongest
activity. Thus, Fr. 2 was further chromatographed to give
corresponding fractions (Frs. 2-1, 2-2, 2-3, 2-4, 2.5, 2.6 and
2-7). The cytotoxicity and tumor-specificity of each
fraction are shown in Table I. 
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Identification of isolated compounds 1-4. Utilizing HPLC,
major cytotoxic substances in Frs. 2-1, 2-2/2-3, 2-4 and 2-5
were isolated as compounds 1, 2, 3 and 4, respectively. On
the basis of spectroscopic analysis including NMR, MS and
comparison with those described in the respective literature,
these compounds were identified as 14-deoxyandrographolide
[1] (6), andrographolide [2] (6), neoandrographolide [3] (7)
and deoxyandrographiside [4] (8), respectively (Figure 1).
Cytotoxic activities of isolated compounds. The cytotoxicities
of isolated compounds are shown in Table II. Among four
isolated compounds, andrographolide had the highest
cytotoxicity against human oral squamous tumor cells (mean
CC50=8.0 μM) and the greatest tumor specificity (TS=9)
(Table II). Neoandrographolide exhibited very weak
cytotoxicity against both human tumor cells and normal
cells. Deoxyandrographiside exhibited 2- to 3-fold lower
cytotoxicity than deoxyandrographolide (Table II). Our
preliminary study demonstrated that treatment of HSC-2
cells with 16 or 32 μM andrographolide induced the cleavage
of PARP and capase-3, suggesting the activation of caspase-
3 (Figure 2).
Suzuki et al: Cytotoxic Isolates from Andrographis paniculata
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Table I. Cytotoxicity of silica gel chromatography fractions prepared from the methanol extract of Andrographis paniculata. The cells were incubated
for 48 h without or with test compounds and the 50% cytotoxic concentration (CC50) value was determined by 3-[4,5-dimethylthiazol-2-yl]-2,5-
diphenyltetrazolium bromide method. Each value represents the mean of triplicate assays.
                                                                                                             CC50 (μg/ml)
                                        Human oral squamous cell carcinoma cell lines              Human normal oral cells
                                 HSC-2               HSC-3              HSC-4               Mean                HGF              HPLF               HPC                Mean            TS
MeOH extr.             34±15                 26±2                 21±7                   28                  67±10              83±26                72±8                   74                3
Fr. 2-1                        36±3                  33±2                  29±1                   32                  193±3              161±5                89±2                  148                5
Fr. 2-2                         7±1                     5±2                    7±1                     5                    41±1                29±0                 12±1                   27                 5
Fr. 2-3                        11±1                    6±0                    7±1                     7                    48±3                29±1                 13±5                   30                 4
Fr. 2-4                        46±5                  39±4                  15±2                   36                   98±6               165±5                >250                 >171              5
Fr. 2-5                       99±6                182±29               97±10                 112                  >250                >250               243±77               >248              2
Fr. 2-6                      131±9                213±7               139±18                145                  >250                >250                 >250                 >250              2
Fr. 2-7                        76±2                 134±5                80±10                  84                  >250                >250                208±6               >236              3
5-FU                           <8                      36                     24                     23                 ˃1000             ˃1000              ˃1000               ˃1000          >43
DXR                         <0.06                  0.21                  0.08                  0.12                 >7.5                >7.5                 >7.5                 >7.5            >63
TS, Tumor-specificity index; HGF, human gingival fibroblast; HPC, human pulp cells; HPLF, human periodontal ligament fibroblast; DXR,
doxorubicin; 5-FU, 5-fluorouracil.
Figure 1. Structures of major cytotoxic compounds from the methanolic extract of Andorgraphis paniculata: 14-deoxyandrographolide [1],
andrographolide [2], neoandrographolide [3] and deoxyandrographiside [4].
Discussion 
The present study identified andrographolide as the major
antitumor principle in the methanolic extract of the leaves
of A. paniculata. During the purification of andrographolide,
the TS value increased from 3 (methanolic extract), to 4-5
(EtOAc partition, followed by silica gel chromatography) to
9 (final purification step with reversed phase HPLC) (Tables
I and II). For the determination of TS, we used human
malignant (HSC-2, HSC-3, HSC-4) and non-malignant
(HGF, HPLF, HPC) cells as target cells, since the TS value
determined by the present method well correlated with their
in vivo antitumor activity, regardless of different cell types
(either epithelial or mesenchymal) (9). For example, 7-
ethyl-10-hydroxycamptothecin (SN-38), the active
metabolite of irinotecan used as clinical antitumor medicine,
had a TS value of 808 by this assay method (10). 
We next considered the structure–activity relationship of
isolated components. The cytotoxicity of andrographolide
against human oral squamous cell carcinoma cell lines
(CC50=8 μM) was higher than that of 14-deoxyandro-
grapholide (CC50=204 μM). The differences in chemical
structure between these compounds are the position of the
double bond on the tetrahydrofuran (endo- or exo-) and
existence of a hydroxyl group connected at C-14. Thus, the
hydroxyl group connected at C-14 and the position of the
olefin bond are important for cytotoxicity against tumor
cells. Furthermore, glycosylation of these diterpenoids
significantly reduced their cytotoxic activity against tumor
cells, as shown by the comparison of neoandrographolide
(CC50 >1,000 μM) and deoxyandrographiside (576 μM).
Based on comparison of the structures of these glycosides,
the existence of a hydroxyl group at the C-3 position is
essential for their cytotoxicity.
The present study demonstrated the possible induction of
apoptosis in HSC-2 cells by andrographolide. Although
induction of apoptosis by andrographolide via nuclear factor-
kappa B inhibition has been reported (11-14), very few
studies have dealt with its tumor specificity (15). It remains
to be investigated why this compound exhibits tumor-
selective cytotoxicity. 
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Table II. Cytotoxicity of isolated compounds 1-4. The cells were incubated for 48 h without or with test compounds and the 50% cytotoxic
concentration (CC50) value was determined by 3-[4,5-dimethylthiazol-2-yl]-2,5-diphenyltetrazolium bromide method. Each value represents the
mean of triplicate assays.
                                                                                                 CC50 (μM)
                            Human oral squamous cell carcinoma cell lines                                   Human normal oral cells
                        HSC-2            HSC-3                HSC-4              Mean                HGF                     HPLF                  HPC               Mean                 TS
1                     259±8.5        267±35.5            327±38.5              204              381±14.5               357±4.5              380±0.5             373                    1
2                      8±1.0             7±1.5                 10±4.0                8.0                151±6.0                 25±0.5               32±11.5              69                    9
3                      >1,000           >1,000                >1,000             >1,000              >1,000                  >1,000                >1,000            >1,000              ><1
4                    509±19.5        489±1.0              729±7.0               576                 >1000                 943±57.5              >1000              >981                 >2
DXR                 0.39                0.45                     0.31                 0.38                  7.5                        7.5                      6.0                  7.0                  18
TS, Tumor specificity index; HGF, human gingival fibroblast; HPC, human pulp cells; HPLF, human periodontal ligament fibroblast; DXR, doxorubicin.
Figure 2. Induction of apotosis by andrographolide [2] in HSC-2 cells.
HSC-2 cells were treated for 24 h with actinomycin D (1 μM)
(apoptosis-positive control) (lane 1), vehicle (negative control) (lane 2),
andrographolide [2] (16, 32 μM) (lane 3, 4), and then processed for
western blot analysis. PARP: Poly (ADP-ribose) polymerase.
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